Acute kidney injury: an acceptable risk of treatment with renin-angiotensin system blockade in primary care?

Background Use of renin-angiotensin system (RAS) blockade has become increasingly widespread driven by evidence-based guidance. There is concern about the role of these agents in the genesis of avoidable acute kidney injury (AKI).